Dabigatran Etexilate (Dabigatran Etexilate Mesylate) Patent Expiration, LOE Window & CMS Spending

Dabigatran Etexilate (Dabigatran Etexilate Mesylate) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 8 AB generics, $77.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$77.4M
2024 Medicare Part D Spend$76.0M
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel